-
Berberine and Evodiamine Modulate GERD via TAS2R38/TRPV1 Pat
2026-05-13
This study demonstrates that the combination of berberine and evodiamine ameliorates gastroesophageal reflux disease (GERD) by targeting bitter taste receptor TAS2R38 and TRPV1, leading to reduced inflammation and improved epithelial integrity. The research provides mechanistic insight into how modulation of these receptors impacts MAPK/NF-κB signaling and macrophage polarization, supporting the development of novel intervention strategies.
-
Puromycin Aminonucleoside: Precision Nephrotoxicity & Podocy
2026-05-13
Puromycin aminonucleoside is the gold-standard agent for inducing podocyte injury and nephrotic syndrome in experimental models. As the aminonucleoside moiety of puromycin, it enables reproducible glomerular lesion induction and proteinuria for renal research. APExBIO's formulation supports high-fidelity modeling of focal segmental glomerulosclerosis (FSGS) and related pathologies.
-
Puromycin Aminonucleoside: Precision Modeling of Podocyte In
2026-05-12
Explore how Puromycin aminonucleoside enables advanced, mechanistically precise modeling of podocyte injury and nephrotic syndrome. This article provides in-depth protocol guidance and bridges next-generation assay design with new molecular insights.
-
MDV3100 (Enzalutamide): AR Antagonism for Prostate Cancer Re
2026-05-12
MDV3100 (Enzalutamide) is a second-generation androgen receptor antagonist with high affinity for the AR ligand-binding domain, widely used in prostate cancer research for apoptosis induction and pathway inhibition. Its efficacy and mechanism are validated in both preclinical and clinical studies, making it a vital tool for investigating castration-resistant prostate cancer and androgen receptor-mediated signaling.
-
Dibutyryl-cAMP, Sodium Salt: Enhancing cAMP Signaling Resear
2026-05-11
Dibutyryl-cAMP, sodium salt enables precise and sustained activation of cAMP pathways, advancing applications in neuronal differentiation and inflammation studies. Its cell-permeability and stability make it the reagent of choice for dissecting protein kinase A activation and gene expression modulation in complex assay systems.
-
PRINT: RNA-Guided Transgene Insertion at Human Safe-Harbor L
2026-05-11
The referenced study introduces PRINT, a method leveraging eukaryotic retroelement proteins for efficient, RNA-mediated transgene insertion at human safe-harbor loci. This approach advances gene therapy by providing site-specific integration without donor DNA, reducing mutagenesis risk and immune activation.
-
Acifran (SKU B6848): Data-Backed Solutions for Lipid Metabol
2026-05-10
This article offers practical, scenario-driven guidance for using Acifran (SKU B6848) to address real laboratory challenges in lipid metabolism research. With insights grounded in published structural biology and assay optimization literature, researchers will find evidence-based answers to common workflow and data interpretation issues. APExBIO's Acifran is positioned as a reliable, selective agonist for robust, reproducible GPCR and lipid signaling studies.
-
Technical Guide: HRP Goat Anti-Rabbit IgG (H+L) Antibody Use
2026-05-09
The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for sensitive and specific secondary antibody detection in immunoassays where rabbit primaries are used. It is optimized for applications such as Western blot, ELISA, and immunohistochemistry, but should not be used in diagnostic or medical workflows. Proper storage and handling are critical to maintain antibody stability and performance.
-
D-Luciferin: Precision Firefly Luciferase Substrate for Biol
2026-05-09
D-Luciferin enables ultra-sensitive, non-invasive bioluminescence imaging for real-time monitoring of gene expression and tumor burden. Learn how to optimize its use in advanced experimental workflows, troubleshoot common pitfalls, and leverage recent immuno-oncology innovations to elevate your research with APExBIO's gold-standard firefly luciferase substrate.
-
Paclitaxel (Taxol): Overcoming Chemoresistance in Cancer Mod
2026-05-08
Explore how Paclitaxel (Taxol) enables advanced cancer research by targeting chemoresistance and cell cycle arrest at the G2-M phase. This article reveals new insights into FOXM1-mediated resistance and provides evidence-backed guidance for experimental design.
-
EP4 Deficiency in Macrophages Accelerates Atherosclerosis vi
2026-05-07
This study uncovers how deficiency of the prostaglandin E2 receptor EP4 in macrophages enhances atherosclerosis progression through CD36-driven lipid uptake and pro-inflammatory polarization. The findings highlight the mechanistic role of EP4 in modulating foam cell formation, offering potential therapeutic insight for cardiovascular disease research.
-
25-Hydroxycholesterol Drives Immunosuppressive Macrophage Pr
2026-05-07
Xiao et al. reveal that 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages activates a lysosomal signaling axis, leading to metabolic reprogramming and enhanced immunosuppressive function. Targeting CH25H, the enzyme producing 25HC, improves anti-tumor immunity and response to checkpoint blockade, advancing our mechanistic understanding of tumor microenvironment immune regulation.
-
Dual Metabolic Nanoplatform Sensitizes Ferroptosis in TNBC T
2026-05-06
This study introduces a metal-polyphenol nanoplatform that co-targets iron and lipid metabolism to enhance ferroptotic therapy in triple-negative breast cancer (TNBC). By integrating dual inhibition of DHODH and DGAT1, the research overcomes compensatory resistance mechanisms, providing a new synergistic approach to address therapeutic challenges in aggressive cancers.
-
5-hme-dCTP: Precision DNA Hydroxymethylation for Epigenetics
2026-05-06
5-hme-dCTP (5-Hydroxymethyl-2’-deoxycytidine-5’-Triphosphate) enables high-fidelity incorporation of 5-hydroxymethylcytosine into DNA for epigenetic modification research. Its validated role in plant gene regulation and stress adaptation makes it a key tool for modern DNA hydroxymethylation assays.
-
SNS-032 (BMS-387032): Selective CDK Inhibition in Oncology &
2026-05-05
SNS-032 (BMS-387032) is a potent, selective inhibitor of CDK2, CDK7, and CDK9. It induces apoptosis in cancer cells and blocks key phosphorylation events in transcriptional control. Recent evidence extends its potential from oncology to antiviral research, with robust quantitative benchmarks.